Clinigen makes second July drug acquisition

Clinigen plans to "revitalise" the treatment, which is also used to reduce the frequency of serious infections in patients with chronic granulomatous disease and is licensed in 19 countries, through working with healthcare professionals.

Horizon will retain the rights to the drug, branded under the name Actimmune, in the US, Canada and Japan.

Shaun Chilton, group chief executive of Clinigen, said: "Imukin strengthens our commercial offering and represents a good strategic fit with our medicines portfolio growth strategy focused on products in oncology and rare diseases."

The AIM-traded company also acquired the global rights outside the US of renal cell carcinoma and melanoma treatment Proleukin from Novartis on 17 July.

David Bryant, chief business officer at Clinigen, said: "Our second acquisition in recent weeks delivers on our long term strategy of acquiring global rights to assets with the aim of revitalising and returning them back to the broadest possible access."

Clinigen’s shares were up 0.1% to 960.00p at 1443 BST.